Kane Biotech

Kane Biotech Liabilities

The The Liabilities of Kane Biotech (KNE.V) as of Oct 21, 2026 is 3.48 M CAD. In the previous year, The Liabilities was 4.12 M CAD — a change of -15.59% (lower).

Liabilities

3.48 MCAD

YoY

-15.59%

Last updated:

In 2025, Kane Biotech's total liabilities amounted to 3.48 M CAD, a -15.59% difference from the 4.12 M CAD total liabilities in the previous year.

The Kane Biotech Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
2.54 M CAD
Jan 1, 2019
1.92 M CAD
Jan 1, 2020
3.96 M CAD
Jan 1, 2021
7.70 M CAD
Jan 1, 2022
9.76 M CAD
Jan 1, 2023
14.09 M CAD
Jan 1, 2024
4.12 M CAD
Jan 1, 2025
3.48 M CAD
The Kane Biotech Liabilities history
YEARLiabilitiesYoY
3.48 MCAD-15.59%
4.12 MCAD-70.74%
14.09 MCAD+44.40%
9.76 MCAD+26.70%
7.70 MCAD+94.43%
3.96 MCAD+106.42%
1.92 MCAD-24.48%
2.54 MCAD+285.53%
659,035.00CAD-15.91%
783,716.00CAD+13.11%
692,863.00CAD+4.27%
664,511.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kane Biotech Stock analysis

What does Kane Biotech do? Kane Biotech, Inc. generates revenue through its portfolio of biotechnology products designed to prevent and remove microbial biofilms. The company commercializes StrixNB, DispersinB, Aledex, bluestem, silkstem, goldstem, coactiv+, and DermaKB Biofilm, with specific focus on the Wound Care & Surgical division developing DispersinB for chronic wound care. The bluestem product line targets animal health markets with water additives, chews, spray, and dental wipes, while Coactiv+ and DispersinB Gel are in development for antimicrobial wound rinse and prosthetic joint infection applications. Additional products include Scalp Detoxifier, Shampoo, and Shampoo Bars for consumer use. Kane Biotech serves animal health markets through its bluestem product line, which includes water additives, chews, spray, and dental wipes. The Wound Care & Surgical division targets medical applications, focusing on DispersinB for chronic wounds and developing Coactiv+ for antimicrobial wound rinse and surgical hydrogel. Consumer products like Scalp Detoxifier, Shampoo, and Shampoo Bars cater to personal care segments. The company's development-stage products such as Coactiv+ antimicrobial surgical hydrogel and DispersinB Gel for prosthetic joint infection represent future revenue streams. The company's primary markets include animal health for bluestem products, medical applications for Wound Care & Surgical division, and consumer personal care for Scalp Detoxifier and Shampoo products. DispersinB is central to the medical division, while bluestem dominates the animal health segment. Development-stage products like Coactiv+ and DispersinB Gel are positioned to address unmet needs in wound care and prosthetic infections, expanding the company's market reach into specialized medical and consumer health segments. Kane Biotech is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Kane Biotech's Liabilities

Kane Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Kane Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Kane Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Kane Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Kane Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Kane Biotech stock

The Liabilities of Kane Biotech is 3.48 M CAD in 2025.

The Liabilities of Kane Biotech changed from 4.12 M CAD to 3.48 M CAD, representing a -15.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Kane Biotech since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Kane Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Kane Biotech

All Key Metrics — Kane Biotech